Statin Therapy for Hypercholesterolemia

Assessment of Cardiovascular Risk

Patients with severe hypercholesterolemia and LDL-C >5.2 mmol/L (>200 mg/dL) are at high risk for atherosclerotic cardiovascular disease (ASCVD), according to the American College of Cardiology and other guidelines 1, 2
An elevated total cholesterol/HDL ratio of 5.9 (normal <4.5) further indicates increased cardiovascular risk, as reported by the European Heart Journal 3
Patients with LDL-C ≥190 mg/dL (4.9 mmol/L) should be considered at high or very high risk of clinical ASCVD, even without other risk factors, as stated by the American College of Cardiology 1, 2

High-intensity statin therapy is recommended as first-line treatment for patients with severe hypercholesterolemia (LDL-C ≥190 mg/dL or 4.9 mmol/L) by the American College of Cardiology 2, 4
The goal is to achieve at least a 50% reduction in LDL-C from baseline, as recommended by the European Heart Journal and the American College of Cardiology 3, 6
For patients with LDL-C of 5.43 mmol/L, the target would be to reduce LDL-C to <2.7 mmol/L, according to the European Heart Journal 3

Initial therapy should start with atorvastatin 40 mg daily, as recommended by the American College of Cardiology and other guidelines 5
Follow-up should include checking lipid panel and liver enzymes 4-12 weeks after initiation, as stated by the American Diabetes Association 4
If LDL-C reduction is <50% or target not achieved, the dose should be increased to atorvastatin 80 mg daily, as recommended by the American College of Cardiology 5
If maximum tolerated statin dose fails to achieve ≥50% LDL-C reduction, ezetimibe 10 mg daily should be added, as recommended by the European Heart Journal and other guidelines 3, 5

Before initiating therapy, secondary causes of hypercholesterolemia (hypothyroidism, chronic kidney disease, obstructive liver disease) should be excluded, as recommended by the American College of Cardiology 1
For patients with familial hypercholesterolemia (FH), more aggressive therapy may be needed, as stated by the European Heart Journal 3

Lipid panel should be obtained 4-12 weeks after initiation or dose change to assess response, as recommended by the American Diabetes Association 4
Long-term monitoring should include annual lipid panels to ensure continued efficacy and adherence, as stated by the American Diabetes Association 4

Starting with insufficient statin intensity is not a prudent use of lipid-lowering therapy, as warned by the American College of Cardiology 6, 7
The goal of therapy is not just to normalize lipid levels but to reduce the risk of cardiovascular events through substantial LDL-C reduction, as emphasized by the American College of Cardiology 6, 7